Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-TN-IV
2024-516734-35-00Phase 3Authorised
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Trodelvy + Keytruda with Standard-of-care chemotherapy (2 arms). Primary endpoints: Event-free survival at 36 months and Pathologic complete response. Planned start Sep 2026; status: authorised.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-516734-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516734-35-00.